BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway that regulates the proliferation and survival of mel...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Proietti, Ilaria, Skroza, Nevena, Michelini, Simone, Mambrin, Alessandra, Balduzzi, Veronica, Bernardini, Nicoletta, Marchesiello, Anna, Tolino, Ersilia, Volpe, Salvatore, Maddalena, Patrizia, Di Fraia, Marco, Mangino, Giorgio, Romeo, Giovanna, Potenza, Concetta
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7408709/
https://ncbi.nlm.nih.gov/pubmed/32645969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071823
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires